Is SZLSF or MRK a better dividend investment in 2026?

SZLSF currently yields 39215.69% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: SZLSF offers higher current income.

What is the dividend yield difference between SZLSF and MRK?

SZLSF has a forward dividend yield of 39215.69% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 39212.93 percentage points.

Home › Compare › SZLSF vs MRK

SZLSF vs MRK: Dividend Comparison 2026

SZLSF yields 39215.69% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SZLSF wins by $4.252735580217355e+22M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SZLSF

● Live price

39215.69%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.252735580217355e+22M

Annual income

$42,315,093,309,418,040,000,000,000,000.00

Full SZLSF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — SZLSF vs MRK

📍 SZLSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SZLSF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SZLSF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SZLSF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZLSF

Annual income on $10K today (after 15% tax)

$3,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$35,967,829,313,005,333,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, SZLSF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZLSF + MRK for your $10,000?

SZLSF: 50%MRK: 50%

100% MRK50/50100% SZLSF

Portfolio after 10yr

$2.1263677901086776e+22M

Annual income

$21,157,546,654,709,020,000,000,000,000.00/yr

Blended yield

99.50%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SZLSF

No analyst data

Altman Z

-336.3

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZLSF buys

MRK buys

No recent congressional trades found for SZLSF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSZLSFMRK

Forward yield	39215.69% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.252735580217355e+22M	$56.8K ✓
Annual income after 10y	$42,315,093,309,418,040,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$4.251340866571809e+22M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: SZLSF vs MRK ($10,000, DRIP)

Year	SZLSF Portfolio	SZLSF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$3,932,269	$3,921,568.63	$11,206	$366.19	+$3.92M → SZLSF
2	$1,445,390,825	$1,441,183,297.58	$12,650	$502.35	+$1445.38M → SZLSF
3	$496,629,048,205	$495,082,480,022.34	$14,407	$694.19	+$496629.03M → SZLSF
4	$159,510,701,964,776	$158,979,308,883,196.16	$16,585	$967.82	+$159510701.95M → SZLSF
5	$47,892,225,784,148,210	$47,721,549,333,045,900.00	$19,342	$1,363.89	+$47892225784.13M → SZLSF
6	$13,442,027,069,357,296,000	$13,390,782,387,768,257,000.00	$22,913	$1,947.19	+$13442027069357.27M → SZLSF
7	$3,526,928,149,355,307,700,000	$3,512,545,180,391,095,400,000.00	$27,662	$2,823.89	+$3526928149355307.50M → SZLSF
8	$865,104,634,553,737,800,000,000	$861,330,821,433,927,700,000,000.00	$34,159	$4,173.35	+$865104634553737856.00M → SZLSF
9	$198,376,161,453,751,100,000,000,000	$197,450,499,494,778,630,000,000,000.00	$43,337	$6,308.80	+$198376161453751107584.00M → SZLSF
10	$42,527,355,802,173,560,000,000,000,000	$42,315,093,309,418,040,000,000,000,000.00	$56,776	$9,798.13	+$4.252735580217355e+22M → SZLSF

SZLSF vs MRK: Complete Analysis 2026

SZLSF — Stock

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

Full SZLSF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this SZLSF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZLSF vs SCHD SZLSF vs JEPI SZLSF vs O SZLSF vs KO SZLSF vs MAIN SZLSF vs JNJ SZLSF vs ABBV SZLSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.